Agreement Between 5 Different Pulse Oximeters Used Simultaneously During a Six-minute Walk Test
Agreement Between 5 Different Pulse Oximeters Used Simultaneously During a Six-minute Walk Test (Concordance Entre Pulse oxymètres Lors d'un Test de Marche standardisé de 6 Minutes)
調査の概要
状態
状態
条件
条件
詳細な説明
51 patients will be included in this study , corresponding to an inclusion period of approximately 3 months.
Patients are all referred for an outpatient pulmonary rehabilitation program for which one or several six-minute walk test (6MWT) is standard procedure.
After the patient has given his/her consent and signed the consent form, they will be fitted with various pulse oximeter sensors (all CE certified and Bluetooth enabled):
- An ear sensor connected to the Nonin Wrist OX2 3150 pulse oximeter
- A flexible digital sensor connected to a Nonin Wrist OX2 3150 pulse oximeter
- A MightySat Rx digital pulse oximeter
- A rigid digital sensor connected to the Masimo Rad-G pulse oximeter
- A Nonin Vantage 9590 digital pulse oximeter from Onyx
The pulse oximeters are placed on the fingers of one hand (chosen according to patient comfort) and a lightweight shoulder strap is used to hold the arm against the abdomen in order to minimise any movement artefacts caused by arm swinging during walking. One of the oximeters is connected to a sensor placed on the earlobe . The last oximeter (Nonin Vantage 9590 from Onyx) is not equipped with Bluetooth transmission and cannot calculate the average or minimum SpO2. However, it is representative of the pulse oximeters commonly acquired and used by patients and caregivers. We will therefore record the results it gives at T0, T6, and at the end of the observation (it will be placed on the free hand).
The patient then receives standardised information about the six-minute walk test procedure (6MWT). The nurse or physiotherapist measures the patient's vital signs at rest: HR, BP, SpO2, dyspnoea on a modified Borg scale.
The 6MWT is then performed for 6 minutes in a marked 30-metre corridor, with standardised information provided every minute until the end of the test, in accordance with international recommendations. The patient is asked to walk at a pace that they think they can maintain for 6 minutes. If they experience excessive dyspnoea, they may sit down and resume the test as soon as they feel able to do so. The test is interrupted if SpO2 falls below 80% (on any of the pulse oximeters). Perceived breathlessness is recorded every minute. SpO2 and HR results are transmitted via Bluetooth to a tablet and can be monitored 'live'.
At the end of the test, the patient sits down and their vital signs are measured for another 2 minutes.
The data obtained during the test is then coded and transferred to an electronic case report form (eCRF) with a numerical code that does not refer to the patient's date of birth or initials.
A list of cases and their codes is kept in a password-protected Excel file, stored by a person outside the study staff.
Inclusion in the protocol takes place at most once per patient.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
Canton of Geneva
-
Meyrin、Canton of Geneva、スイス、1217
- Hôpital de La Tour
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- All patients referred to our Cardiorespiratory Unit for a pulmonary rehabilitation programme
- Aged over 18, no maximum age limit
- Absence of language barriers or cognitive impairments that would make it impossible to explain the protocol
- Resting SpO2 > 90%
- Signing the informed consent form after receiving detailed information about the study.
Exclusion Criteria:
- Any clinical condition that makes it impossible or compromises the performance of a walking test: unstable heart disease, acute myocarditis and/or pericarditis, acute arrhythmia, severe pulmonary hypertension, deep vein thrombosis, severe asthma, acute orthopaedic or rheumatic condition
- Unstable clinical condition (patient hospitalised or less than 4 weeks after an exacerbation leading to hospitalisation)
- Oxygen therapy at rest and/or during walking
- Uncontrolled arterial hypertension (AHT) at rest
- Known cardiac rhythm disorder
- Unexplained chest pain at rest
- Mechanical interference with the possibility of placing pulse oximeters: skin lesions, bandages, plaster casts, etc.
- Withdrawal of consent during the study
- Systemic scleroderma, sclerodactyly, history of any type of vasculitis
- Symptomatic Raynaud's phenomenon
- Marked clubbing
- Known haemoglobinopathy
- Refusal to remove nail polish
研究計画
研究はどのように設計されていますか?
デザインの詳細
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
|---|
|
Study group
All patients undergo the same simultaneous measurement of oxygen saturation with 5 different devices.
No randomisation, no sham device.
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Limits of agreement between devices for oxygen saturation (SpO2) at the end of a six-minute walk test.
時間枠:Baseline
|
An analysis according to the Bland and Altman method comparing devices by pairs allows to determine the bias (mean error) and the limits of agreement for the SpO2 measured at the end of the walk test.
|
Baseline
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Limits of agreement between devices for heart rate at T0 (start of test), T6 (end of test) and maximal and minimal values
時間枠:Baseline
|
Same analysis as primary outcome
|
Baseline
|
|
Agreement between devices for identifying subjects who have a significant drop in SpO2 (desaturate) during the six-minute walk test
時間枠:Baseline
|
Subjects will be identified as desaturating or not according to 5 pre-defined criteria (minimal SpO2 < or = 90%, < or = 88%; mean SpO2 < or = 90%, < or = 88%; presence or absence of a drop in SpO2 > or = 4% between T0 and minimal value recorded)
|
Baseline
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- 2024-02489
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。